Zacks Analyst Blog Highlights: AMAG Pharmaceuticals Inc., Fresenius Medical Care AG & Co., Watson Pharmaceuticals, Inc., Sanofi-Aventis and ReneSola Ltd.

For Immediate Release

Chicago, IL – July 15, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report), Fresenius Medical Care AG & Co. (FMS - Snapshot Report), Watson Pharmaceuticals, Inc. (WPI - Snapshot Report), Sanofi-Aventis (SNY - Analyst Report) and ReneSola Ltd. (SOL - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

AMAG Kidney Drug Launched

AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report) launched the Feraheme (ferumoxytol) Injection in the U.S. It is an intravenous iron replacement therapy to fight anemia in patients with chronic kidney disease. The drug can be used by patients irrespective of them undergoing dialysis.

Wholesalers and specialty distributors will primarily distribute Feraheme in the U.S. More specifically, AMAG will use approximately 150 seasoned professionals which includes a 80-person specialized sales force to sell and market the drug. For every 510 mg vial, the wholesale acquisition cost (WAC) of Feraheme is $396.78.

Iron deficiency anemia is a significant problem in patients with chronic kidney disease and often goes underdiagnosed and undertreated. We feel peak sales of Feraheme could reach $500 million.

As a reminder, Feraheme is AMAG’s lead anti-anemia drug candidate. The company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the marketing approval of Feraheme on December 19, 2007. The NDA filing was accepted by the FDA in February 2008; eventually the FDA established December 30, 2008 as its target action date under the Prescription Drug User Fee Act (PDUFA) to complete its review.

However, on Dec 22, 2008, AMAG received a second Complete Response letter from the FDA, requiring additional information. The company responded to the issues raised letter which was accepted on May 12, 2009. Finally, the agency approved the kidney drug on June 30.

Even though we are pleased to hear about Feraheme’s approval and subsequent U.S. launch, we are aware of the stiff competition awaiting AMAG’s drug in the IV iron replacement therapy market. Venofer from Fresenius Medical Care AG & Co. (FMS - Snapshot Report) and Ferrlecit from Watson Pharmaceuticals, Inc. (WPI - Snapshot Report)/ Sanofi-Aventis (SNY - Analyst Report) are AMAG’s main competitors in this market.

ReneSola Plays It Smart

China-based ReneSola Ltd. (SOL - Analyst Report) is playing it smart, making its presence felt in the entire solar energy chain.

Earlier today, ReneSola announced the successful commencement of its trial production of the Phase One of its polysilicon manufacturing facility located in China's Sichuan province. The 3,000 MT polysilicon plant with two phases of 1,500 MT annualized capacity each, is slated to reach mechanical completion in September 2009.

With the inclusion of polysilicon in its product portfolio, the company’s strategy to be present in the entire solar chain was more or less completed.

In its short life span since 2005, the company started with producing high cost monocrystalline wafers only. However, since the third quarter of 2007 it branched out to manufacturing, volume accretive multicrystalline wafers also.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/ZacksInvestment

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com